NEWS

Modena files patent infringement lawsuit in Europe against Pfizer and Biotech

Release time:

2022-10-28 09:39

 

Modena (Moderna) in the District Court of Düsseldorf, Germany (Case No:4b O 62/22) and the United States on itsmRNAVaccines against Pfizer (Pfizer) and Biotech (BioNTech) File a pauntly Lawfollow.

 

In Germany, Modena argues that Pfizer and Biotech are infringing them.CompanyThe two patents (EP 35 90 949,EP 37 18 565) and claim damages. The action is for damages only, not injunctive relief. Modena is likely to choose this approach to ensure their right to supply vaccines to the public. During the severe period of the previous neo-coronavirus pandemic,mRNAIn order to avoid causing political and social unrest, patentees are usually hesitant to file related lawsuits against competitors.

 

The U.S. lawsuit has now been made public, while the German one has not yet been made public. Modena's press release indicates the motivation: they believe that Pfizer and New Biotechnology have copied two key technical characteristics of Modena's patented technology, which has a significant impact onmRNASuccessful vaccine development is crucial.

 

According to Modena, Pfizer andBioNTechFour different vaccine candidates were put into clinical testing, including options that could circumvent the innovation developed by Modena. However, Pfizer and Biotech eventually decided to go ahead and develop a vaccine with Modena (Spikevax®) have the samemRNAChemically modified vaccines.

 

Furthermore, despite many different options, Pfizer and New Biotechnology have followed Modena's approach, which is to encode the full-length spike protein in a lipid nanoparticle formulation of the coronavirus. Modner claimed that they were developing Middle East Respiratory Syndrome (MERS) when the coronavirus vaccine was developed, several years before the new coronavirus first appeared.

 

According to Modena, Pfizer and Biotech's new coronavirus vaccine violated Modena's 2010Year2016Submissions during the year cover the Modena FoundationmRNAPatents of technology. This breakthrough technology is essential for the development of Modena'smRNAnew coronavirus vaccineSpikevaxCrucial.

 

RelatedExperts have long suspected that, like this caseInfringementThe lawsuit is not against a competitor's new coronavirus vaccine. On the contrary,behind its possibleIs for the futuremRNAThe development of drugs paves the way.

 

Lawsuit, vaccine, company, mrna, pfizer, bio, virus, think, they